Biotech Values

[DewDiligence]

…the distinction of who is selling the AG matters? To the best of my knowledge the MNTA-Sandoz contract has no regard to who is selling it.

Correct and crystal clear. Unlike the discussion we had about a fixed vs variable threshold for the profit-share mode under an AG, the lack of distinction in the NVS-MNTA Lovenox agreement about who sells the AG does not require any decoding of the redacted text.